Myriad launches #ProstateAnswers social media campaign to help educate the public about prostate cancer and genetic testing

SALT LAKE CITY, UT USA (Press Release) - January 26, 2015 - Myriad Genetics, Inc. a leader in molecular diagnostics and the makers of the Prolaris genetic test for prostate cancer, today announced the launch of the #ProstateAnswers social media campaign on January 26 to raise public health awareness about genetic testing for men with prostate cancer. Prostate cancer is a complex disease. After diagnosis, men and their doctors may struggle over whether more aggressive treatment is needed (i.e., surgery, radiation, chemotherapy) or if active surveillance is the more appropriate course. The #ProstateAnswers campaign is designed to help answer these important and pressing health questions.

"Our goal is to inform the public about prostate cancer and genetic testing. We regularly hear from patients that knowledge is power and they want more and better genetic information about their prostate cancer to help protect themselves and their futures," said Ron Rogers, executive vice president, Corporate Communications Myriad Genetics. "By encouraging prostate cancer community to use the #ProstateAnswers hashtag, we're inviting many thousands of people to join us in the fight against prostate cancer and help change the equation for men diagnosed with this disease, which unfortunately, remains a leading cause of cancer death among men."

The #ProstateAnswers campaign encourages healthcare professionals, prostate cancer survivors, patient advocacy organizations and social media fans and followers to unite in the fight against prostate cancer by going to http://bit.ly/1JiTLgi to learn more and sharing their experiences with prostate cancer.

We recommend they craft their own messages using the #ProstateAnswers hashtag on Facebook, Twitter and LinkedIn, and highlighting the following key statistics:

  • 1 in 7 men will be diagnosed with prostate cancer in his lifetime
  • About 1 in 36 men with prostate cancer will die from the disease
  • 65% of treatment plans for men with prostate cancer changed results from the Prolaris test.



Ron Rogers
Executive Vice President
Corporate Communications
Myriad Genetics Inc.
801-584-3065 (office)
908-285-0248 (cell)
@rogersro (Twitter)

###

Myriad Genetics, Inc.

 

[ PRESS RELEASE ]

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe